WZ3146 is primarily used as a selective inhibitor of the MET tyrosine kinase receptor, making it a valuable tool in cancer research, particularly in studies involving tumor growth, metastasis, and signaling pathways driven by MET activation. It has been applied in preclinical studies to investigate the role of MET in various cancers, including lung, liver, and gastric cancers. Due to its ability to suppress MET phosphorylation and downstream signaling, WZ3146 helps researchers evaluate the therapeutic potential of MET inhibition. It is also used in combination studies with other targeted agents or chemotherapeutics to assess synergistic effects and overcome drug resistance. Its application remains confined to laboratory and experimental settings, mainly in cell-based assays and animal models.